Current problems in cancer. Case reports最新文献

英文中文

Mesonephric-like adenocarcinoma of the ovary: A rare case report and review of the literature

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-02-09 DOI: 10.1016/j.cpccr.2025.100355

Maryam Hosseinirad , Elham Mirzaeian , Amirhossein Charejoo

Mesonephric-like adenocarcinoma of the ovary is an exceedingly rare malignant tumor within the reproductive system, accounting for fewer than 1 % of all malignant tumors in women. Originating from remnants of the regressed Wolffian duct during embryonic development, its clinical manifestations are nonspecific, and its rarity often leads to delayed diagnosis, resulting in heightened morbidity and long-term recurrence. We discuss a case of 57-year-old woman with ovarian cysts that were incidentally found in abdominal and pelvic sonography and final diagnosis of mesonephric-like adenocarcinoma with peritoneal involvement and 2014 FIGO stage classification of stage IIIc which is extremely rare stage at presentation in this particular tumor. Diagnosis primarily relies on meticulous physical examination coupled with imaging, complemented by histological analysis and the tracking of diagnostic immunohistochemical markers (positive for TTF1, GATA3, PAX8, and CD10 while conversely negative for ER and PR). This study elucidates the clinical and pathophysiological attributes, diagnostic findings, and treatment strategies through the analysis of a subset of patients diagnosed with mesonephric-like adenocarcinoma in the ovary, followed by a comprehensive literature review.

{"title":"Mesonephric-like adenocarcinoma of the ovary: A rare case report and review of the literature","authors":"Maryam Hosseinirad , Elham Mirzaeian , Amirhossein Charejoo","doi":"10.1016/j.cpccr.2025.100355","DOIUrl":"10.1016/j.cpccr.2025.100355","url":null,"abstract":"<div><div>Mesonephric-like adenocarcinoma of the ovary is an exceedingly rare malignant tumor within the reproductive system, accounting for fewer than 1 % of all malignant tumors in women. Originating from remnants of the regressed Wolffian duct during embryonic development, its clinical manifestations are nonspecific, and its rarity often leads to delayed diagnosis, resulting in heightened morbidity and long-term recurrence. We discuss a case of 57-year-old woman with ovarian cysts that were incidentally found in abdominal and pelvic sonography and final diagnosis of mesonephric-like adenocarcinoma with peritoneal involvement and 2014 FIGO stage classification of stage IIIc which is extremely rare stage at presentation in this particular tumor. Diagnosis primarily relies on meticulous physical examination coupled with imaging, complemented by histological analysis and the tracking of diagnostic immunohistochemical markers (positive for TTF1, GATA3, PAX8, and CD10 while conversely negative for ER and PR). This study elucidates the clinical and pathophysiological attributes, diagnostic findings, and treatment strategies through the analysis of a subset of patients diagnosed with mesonephric-like adenocarcinoma in the ovary, followed by a comprehensive literature review.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100355"},"PeriodicalIF":0.2,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Streptococcus gallolyticus endocarditis, a silent sign for colonic cancer: Case report and literature review

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-02-07 DOI: 10.1016/j.cpccr.2025.100354

Youssef Lahmouz, Zaynab Mouhib, Najat Mouine, Hicham Bouzelmat, Ali Chaib, Aatif Benyass

We describe the case of a 81-year-old male patient with Cardiac device-related endocarditis caused by Streptococcus gallolyticus (Sgg) and colonic adenocarcinoma with fatal neurological complications. It is important to highlight the need for thorough colon examination, even in asymptomatic individuals, when diagnosing infective endocarditis caused by Sgg.

引用次数: 0

Incidental encounters – unveiling neuroendocrine neoplasms in routine upper gastrointestinal endoscopy: A case series

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-02-06 DOI: 10.1016/j.cpccr.2025.100356

Dr. Mitali M․ Rath , Dr. Rashmi Patnayak , Dr. Shiva Dhala Mohapatra , Dr. Prakash Chandra Dalei

Introduction

Neuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract or pancreas are collectively called Gastroenteropancreatic NENs (GEP-NENs). The incidence and prevalence of these tumors is on a rise, owing to higher awareness and advanced diagnostic modalities. Many of them are incidentally detected during endoscopy or cross-sectional imaging. Here we present nine cases of GEP-NENs which were detected incidentally during their hospital visit for various GI complaints.

Method

Upper GI endoscopic biopsy was performed in 1052 patients at this single institution. Routine histopathology, and when needed, immunohistochemistry (IHC) tests were carried out. Final diagnosis of NEN was made on the basis of the 2019 WHO classification.

Result

Nine cases were histologically confirmed having NEN. The lesions were located in the duodenum in six cases and in the stomach in three. All except one were Grade 1 neuroendocrine tumors (NET), one patient had grade 2 NET. In three cases the NET was limited to mucosa and submucosal invasion was seen in six cases. Patients were managed with polypectomy(n = 2), endoscopic mucosal resection (EMR)(n = 2), endoscopic submucosal dissection (ESD)(n = 3), surgical resection(n = 1) and no therapeutic intervention, only regular follow up (n = 1)

Discussion

All polypoidal or submucosal lesions of the GI tract may be biopsied to avoid missing out GEP-NENs. New and advanced techniques of GI endoscopy play a pivotal role in diagnosis and management of GEP-NENs. Here we are sharing our experience of upper GI tract NENs at a single gastroenterology super speciality centre in Eastern India.

{"title":"Incidental encounters – unveiling neuroendocrine neoplasms in routine upper gastrointestinal endoscopy: A case series","authors":"Dr. Mitali M․ Rath , Dr. Rashmi Patnayak , Dr. Shiva Dhala Mohapatra , Dr. Prakash Chandra Dalei","doi":"10.1016/j.cpccr.2025.100356","DOIUrl":"10.1016/j.cpccr.2025.100356","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract or pancreas are collectively called Gastroenteropancreatic NENs (GEP-NENs). The incidence and prevalence of these tumors is on a rise, owing to higher awareness and advanced diagnostic modalities. Many of them are incidentally detected during endoscopy or cross-sectional imaging. Here we present nine cases of GEP-NENs which were detected incidentally during their hospital visit for various GI complaints.</div></div><div><h3>Method</h3><div>Upper GI endoscopic biopsy was performed in 1052 patients at this single institution. Routine histopathology, and when needed, immunohistochemistry (IHC) tests were carried out. Final diagnosis of NEN was made on the basis of the 2019 WHO classification.</div></div><div><h3>Result</h3><div>Nine cases were histologically confirmed having NEN. The lesions were located in the duodenum in six cases and in the stomach in three. All except one were Grade 1 neuroendocrine tumors (NET), one patient had grade 2 NET. In three cases the NET was limited to mucosa and submucosal invasion was seen in six cases. Patients were managed with polypectomy(<em>n</em> = 2), endoscopic mucosal resection (EMR)(<em>n</em> = 2), endoscopic submucosal dissection (ESD)(<em>n</em> = 3), surgical resection(<em>n</em> = 1) and no therapeutic intervention, only regular follow up (<em>n</em> = 1)</div></div><div><h3>Discussion</h3><div>All polypoidal or submucosal lesions of the GI tract may be biopsied to avoid missing out GEP-NENs. New and advanced techniques of GI endoscopy play a pivotal role in diagnosis and management of GEP-NENs. Here we are sharing our experience of upper GI tract NENs at a single gastroenterology super speciality centre in Eastern India.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100356"},"PeriodicalIF":0.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oropharyngeal metastasis of merkel cell carcinoma: Case report and review of the literature

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-01-26 DOI: 10.1016/j.cpccr.2025.100352

John S. Howard , Trisha Wise-Draper , Kevin Redmond , Rebecca Howell , Steven D. Gilday , Dustin A. Silverman

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin, most commonly affecting sun exposed areas of the head and neck in older patients. Surgery remains the mainstay of treatment followed by adjuvant radiation or chemoradiation therapy in appropriately selected patients. Though MCC is associated with high rates of locoregional recurrence and propensity for distant metastases, metastatic disease involving the oropharynx is exceedingly rare; the optimal therapeutic approach in this setting remains controversial. Herein, we report a rare case of metastatic MCC to the base of tongue presenting as acute oropharyngeal hemorrhage in an 86-year-old male without an identifiable primary lesion. Definitive airway management and treatment with tumor-directed radiation and concurrent pembrolizumab were successful in this case. Optimal diagnostic and treatment strategies are discussed in addition to a review of the literature for patients with metastatic MCC affecting the oropharynx. Further, the role of transoral robotic surgery (TORS), systemic chemotherapeutic regimens, and immunotherapy in this setting are highlighted.

{"title":"Oropharyngeal metastasis of merkel cell carcinoma: Case report and review of the literature","authors":"John S. Howard , Trisha Wise-Draper , Kevin Redmond , Rebecca Howell , Steven D. Gilday , Dustin A. Silverman","doi":"10.1016/j.cpccr.2025.100352","DOIUrl":"10.1016/j.cpccr.2025.100352","url":null,"abstract":"<div><div>Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin, most commonly affecting sun exposed areas of the head and neck in older patients. Surgery remains the mainstay of treatment followed by adjuvant radiation or chemoradiation therapy in appropriately selected patients. Though MCC is associated with high rates of locoregional recurrence and propensity for distant metastases, metastatic disease involving the oropharynx is exceedingly rare; the optimal therapeutic approach in this setting remains controversial. Herein, we report a rare case of metastatic MCC to the base of tongue presenting as acute oropharyngeal hemorrhage in an 86-year-old male without an identifiable primary lesion. Definitive airway management and treatment with tumor-directed radiation and concurrent pembrolizumab were successful in this case. Optimal diagnostic and treatment strategies are discussed in addition to a review of the literature for patients with metastatic MCC affecting the oropharynx. Further, the role of transoral robotic surgery (TORS), systemic chemotherapeutic regimens, and immunotherapy in this setting are highlighted.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100352"},"PeriodicalIF":0.2,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obscure pulmonary artery intimal sarcoma presenting with hemoptysis and pulmonary embolism

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-01-13 DOI: 10.1016/j.cpccr.2025.100351

Daniel Cheah , Rachael Wong , Sushan Gupta , Frank Bellafiore , Paramesh Dakshinesh

Pulmonary artery intimal sarcoma (PAIS) is a rare and highly malignant neoplasm that presents similarly to pulmonary embolism. Due to the rarity of presentation and high mortality, there is limited data on its heterogeneous presentation, epidemiology, and treatment. We present a case of pulmonary artery intimal sarcoma mimicking features of pneumonia and pulmonary embolism. Our patient was a 43-year-old non-smoker male with no past medical history who presented with a cough with hemoptysis. Initial CT imaging showed acute right pulmonary embolism with right lung pulmonary infarct. The patient was treated with anticoagulation. On follow-up, he continued to complain of hemoptysis. Repeat CT lung now showed a moderate-sized right hilar mass. Endobronchial ultrasound-guided fine needle aspiration biopsy of the hilar mass with bronchial lavage showed malignant cells with immunohistochemistry positive for vimentin. The patient underwent a right pneumonectomy when he was later diagnosed with pulmonary artery intimal sarcoma. He was subsequently started on epirubicin, ifosfamide, and mesna and is currently on 3-monthly CT surveillance with no disease recurrence.

{"title":"Obscure pulmonary artery intimal sarcoma presenting with hemoptysis and pulmonary embolism","authors":"Daniel Cheah , Rachael Wong , Sushan Gupta , Frank Bellafiore , Paramesh Dakshinesh","doi":"10.1016/j.cpccr.2025.100351","DOIUrl":"10.1016/j.cpccr.2025.100351","url":null,"abstract":"<div><div>Pulmonary artery intimal sarcoma (PAIS) is a rare and highly malignant neoplasm that presents similarly to pulmonary embolism. Due to the rarity of presentation and high mortality, there is limited data on its heterogeneous presentation, epidemiology, and treatment. We present a case of pulmonary artery intimal sarcoma mimicking features of pneumonia and pulmonary embolism. Our patient was a 43-year-old non-smoker male with no past medical history who presented with a cough with hemoptysis. Initial CT imaging showed acute right pulmonary embolism with right lung pulmonary infarct. The patient was treated with anticoagulation. On follow-up, he continued to complain of hemoptysis. Repeat CT lung now showed a moderate-sized right hilar mass. Endobronchial ultrasound-guided fine needle aspiration biopsy of the hilar mass with bronchial lavage showed malignant cells with immunohistochemistry positive for vimentin. The patient underwent a right pneumonectomy when he was later diagnosed with pulmonary artery intimal sarcoma. He was subsequently started on epirubicin, ifosfamide, and mesna and is currently on 3-monthly CT surveillance with no disease recurrence.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100351"},"PeriodicalIF":0.2,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-01-11 DOI: 10.1016/j.cpccr.2025.100349

Jialin Qian, Tianqing Chu

Background

Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance.

Case description

A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled.

Conclusions

Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients.

{"title":"Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report","authors":"Jialin Qian, Tianqing Chu","doi":"10.1016/j.cpccr.2025.100349","DOIUrl":"10.1016/j.cpccr.2025.100349","url":null,"abstract":"<div><h3>Background</h3><div>Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance.</div></div><div><h3>Case description</h3><div>A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled.</div></div><div><h3>Conclusions</h3><div>Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100349"},"PeriodicalIF":0.2,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of outcomes in a veteran treated with lurbinectedin long-term for extensive-stage small cell lung cancer: A case report

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-01-10 DOI: 10.1016/j.cpccr.2025.100350

Jana Sawyer , Megan Banaszynski , Brian Do , Jesse Cobell

Small cell lung cancer comprises approximately 10% to 15% of all lung cancers but is associated with a high proliferation rate and poor prognosis. Treatment options for patients with small cell lung cancer have been limited and offer modest clinical benefit. Lurbinectedin, an approved treatment by the United States Food and Drug Administration for metastatic small cell lung cancer in adults with disease progression during or after platinum-based chemotherapy, was shown to have antitumor activity and a favorable safety profile in a phase II trial. Here, we present a case report of a patient who was treated with lurbinectedin for approximately 2 years and maintained stable disease while receiving a reduced dose. The patient developed grade 3 anemia which resolved following a dose reduction of lurbinectedin, allowing for mitigation of toxicity while maintaining the clinical efficacy of the drug. Clinicians who treat patients with small cell lung cancer should be aware of this extended use of lurbinectedin in a patient who relapsed following first-line treatment and maintained stable disease on a reduced dose for almost 2 years.

{"title":"Review of outcomes in a veteran treated with lurbinectedin long-term for extensive-stage small cell lung cancer: A case report","authors":"Jana Sawyer , Megan Banaszynski , Brian Do , Jesse Cobell","doi":"10.1016/j.cpccr.2025.100350","DOIUrl":"10.1016/j.cpccr.2025.100350","url":null,"abstract":"<div><div>Small cell lung cancer comprises approximately 10% to 15% of all lung cancers but is associated with a high proliferation rate and poor prognosis. Treatment options for patients with small cell lung cancer have been limited and offer modest clinical benefit. Lurbinectedin, an approved treatment by the United States Food and Drug Administration for metastatic small cell lung cancer in adults with disease progression during or after platinum-based chemotherapy, was shown to have antitumor activity and a favorable safety profile in a phase II trial. Here, we present a case report of a patient who was treated with lurbinectedin for approximately 2 years and maintained stable disease while receiving a reduced dose. The patient developed grade 3 anemia which resolved following a dose reduction of lurbinectedin, allowing for mitigation of toxicity while maintaining the clinical efficacy of the drug. Clinicians who treat patients with small cell lung cancer should be aware of this extended use of lurbinectedin in a patient who relapsed following first-line treatment and maintained stable disease on a reduced dose for almost 2 years.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100350"},"PeriodicalIF":0.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mTOR inhibition with sirolimus is associated with a durable response in HIV associated multifocal Epstein-Barr Virus associated smooth muscle Tumour (EBV-SMT) and mini review of novel therapeutic options

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-01-09 DOI: 10.1016/j.cpccr.2024.100344

John Kh Ang , Daniel Ry Yap , Khoon Leong Chuah , Jens Samol

Epstein-Barr Virus associated smooth muscle tumour (EBV-SMT) is a rare tumour with an estimated prevalence of <2 cases per million. It develops in patients who are immunocompromised and in whom the risk of EBV reactivation causing tumorigenesis is high. Examples of immunocompromised states include patients infected with human immunodeficiency virus (HIV), patients on iatrogenic immunosuppression following transplantation and patients with primary/congenital immunodeficiency. Although the association between EBV and development of EBV-SMT is well established, the underlying pathophysiology for this association is unclear.

We present a case of a patient with HIV related EBV-SMT who has been on treatment with sirolimus for >5 years with disease continuing to remain controlled, clearly demonstrating the durable activity of sirolimus in the management of EBV-SMT. We scrutinized the literature pertaining to novel therapeutics which have been used for the management of EBV-SMTs and set it into context with other EBV associated neoplasms.

To our knowledge, this is the first case report of a patient treated with sirolimus and we recommend that mTOR inhibition with sirolimus be considered as a first therapeutic option together with HAART in patients with HIV associated EBV-SMTs.

{"title":"mTOR inhibition with sirolimus is associated with a durable response in HIV associated multifocal Epstein-Barr Virus associated smooth muscle Tumour (EBV-SMT) and mini review of novel therapeutic options","authors":"John Kh Ang , Daniel Ry Yap , Khoon Leong Chuah , Jens Samol","doi":"10.1016/j.cpccr.2024.100344","DOIUrl":"10.1016/j.cpccr.2024.100344","url":null,"abstract":"<div><div>Epstein-Barr Virus associated smooth muscle tumour (EBV-SMT) is a rare tumour with an estimated prevalence of <2 cases per million. It develops in patients who are immunocompromised and in whom the risk of EBV reactivation causing tumorigenesis is high. Examples of immunocompromised states include patients infected with human immunodeficiency virus (HIV), patients on iatrogenic immunosuppression following transplantation and patients with primary/congenital immunodeficiency. Although the association between EBV and development of EBV-SMT is well established, the underlying pathophysiology for this association is unclear.</div><div>We present a case of a patient with HIV related EBV-SMT who has been on treatment with sirolimus for >5 years with disease continuing to remain controlled, clearly demonstrating the durable activity of sirolimus in the management of EBV-SMT. We scrutinized the literature pertaining to novel therapeutics which have been used for the management of EBV-SMTs and set it into context with other EBV associated neoplasms.</div><div>To our knowledge, this is the first case report of a patient treated with sirolimus and we recommend that mTOR inhibition with sirolimus be considered as a first therapeutic option together with HAART in patients with HIV associated EBV-SMTs.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100344"},"PeriodicalIF":0.2,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2025-01-01 DOI: 10.1016/j.cpccr.2024.100348

Alexander S Watson, Tejas Patil, Erin L Schenk, D Ross Camidge

The bispecific antibody amivantamab has evidence in multiple combinations and indications for treating advanced Epidermal Growth Factor Receptor (EGFR) mutated NSCLC, including a recently approved first line combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib. Thrombotic complications have been reported at elevated rates for amivantamab-lazertinib combinations in clinical trials. While awaiting lazertinib approval, the previously established third-generation EGFR TKI osimertinib has been utilized by some clinicians in combinations with amivantamab, and this substitution will likely continue to be used in certain clinical contexts. Whether osimertinib-amivantamab combinations also carry thrombotic risk has not been described. Here, we outline three patient cases from our institution where osimertinib-amivantamab combinations were employed, highlighting early development of venous thromboembolism, arterial thrombosis, and use of anticoagulation prophylaxis. We review these cases in the context of the existing literature exploring thrombotic complications with amivantamab combinations. Clinicians should be aware of, discuss with patients, and take steps to mitigate, thrombotic risk with amivantamab-EGFR TKI combination therapy.

{"title":"Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review","authors":"Alexander S Watson, Tejas Patil, Erin L Schenk, D Ross Camidge","doi":"10.1016/j.cpccr.2024.100348","DOIUrl":"10.1016/j.cpccr.2024.100348","url":null,"abstract":"<div><div>The bispecific antibody amivantamab has evidence in multiple combinations and indications for treating advanced Epidermal Growth Factor Receptor (EGFR) mutated NSCLC, including a recently approved first line combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib. Thrombotic complications have been reported at elevated rates for amivantamab-lazertinib combinations in clinical trials. While awaiting lazertinib approval, the previously established third-generation EGFR TKI osimertinib has been utilized by some clinicians in combinations with amivantamab, and this substitution will likely continue to be used in certain clinical contexts. Whether osimertinib-amivantamab combinations also carry thrombotic risk has not been described. Here, we outline three patient cases from our institution where osimertinib-amivantamab combinations were employed, highlighting early development of venous thromboembolism, arterial thrombosis, and use of anticoagulation prophylaxis. We review these cases in the context of the existing literature exploring thrombotic complications with amivantamab combinations. Clinicians should be aware of, discuss with patients, and take steps to mitigate, thrombotic risk with amivantamab-EGFR TKI combination therapy.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100348"},"PeriodicalIF":0.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transformation of PSMA-avid to FDG-avid disease in metastatic castration-resistant prostate cancer in the setting of biochemical response with LU177-PSMA-617

IF 0.2 Q4 ONCOLOGY

Current problems in cancer. Case reports

Pub Date : 2024-12-31 DOI: 10.1016/j.cpccr.2024.100347

A Sidhu , P Singh

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Current problems in cancer. Case reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀